-
How Cell Divisions Refine Drosophila Tissue Boundaries
2026-09-24
Castle and colleagues show that ectodermal cell divisions have a dual effect at the Drosophila mesectoderm–ectoderm boundary: they can challenge separation, yet also promote boundary linearity by lowering junctional tension and increasing cell movement. The study combines mathematical modelling, division perturbation, laser ablation and cell tracking to reveal a division-driven route to tissue refinement that complements actomyosin-based boundary tension.
-
ISR Inhibition and Accelerated Forgetting in Epilepsy
2026-09-23
A 2025 Molecular Neurobiology study identifies integrated stress response activation as a molecular correlate of both natural forgetting and seizure-associated accelerated forgetting in mice. By administering ISRIB during memory retention, the authors preserved recognition memories and corrected PTZ-induced forgetting, highlighting the retention phase as a potential intervention window.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-09-23
The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic drift in skeletal muscle fibro/adipogenic progenitors. Its integrated use of pharmacological perturbation, mass cytometry, transcriptomics, network modeling, and mouse injury models links restored β-catenin activity with reduced muscle fat accumulation and improved support of satellite-cell differentiation.
-
Fenipentol Workflows for Secretion and Fibrosis
2026-09-22
Fenipentol is a defined small-molecule tool for connecting hepatobiliary secretion, ESR1-oriented hypotheses, and translational liver assays. This workflow explains how to prepare, dose, compare, and troubleshoot Fenipentol while clearly separating direct evidence from findings on its positional isomer.
-
Talabostat mesylate: Reliable Assay Design
2026-09-21
This scenario-based guide explains how Talabostat mesylate (SKU B3941) can support mechanistic cell viability, cytotoxicity, and tumor microenvironment studies. It connects formulation handling, keratinocyte inflammasome evidence, FAP-dependent comparisons, and practical vendor-selection criteria to improve interpretation and workflow consistency.
-
From RNA Modification Maps to Translational Strategy
2026-09-21
Spatially resolved RNA modification profiling is shifting the field from cataloging chemical marks to understanding where modified RNAs act. This article examines how APEX-RNA-MS, orthogonal validation, and carefully controlled use of IMP can help translational researchers convert cellular localization signals into testable biological and development hypotheses.
-
ERADECs for Targeted Degradation of TM Proteins
2026-09-20
Song et al. establish ERAD-engaging chimeras (ERADECs), a small-molecule platform that redirects the ER-associated degradation pathway toward transmembrane proteins. By identifying desonide as a binder of the ER E3 ligase SYVN1 and applying it to PD-L1 degradation, the study provides a mechanistic route for overcoming limitations of lysosome- and proteasome-oriented targeted protein degradation.
-
Anti-b Targets mTOR-Linked Hepatic Steatosis
2026-09-19
A 2025 British Journal of Pharmacology study shows that Anti-b reduces diet- and oleic acid-induced dyslipidaemia and hepatic lipid accumulation in rodents and liver cells. Its mechanistic contribution is the integration of mTOR binding and thermal-stability evidence with PPARγ and SREBP1 pathway analysis, providing a basis for studying mTOR-linked lipid metabolism.
-
KG-501: Mapping CREB Control in CAC Models
2026-09-19
KG-501 provides a pharmacological way to interrogate CREB–CBP coactivator control in colitis-associated cancer models. This article distinguishes direct transcriptional effects from TLR4 pathway dependence and presents an assay framework grounded in the Liu et al. study.
-
DNase I (RNase-free): From Clean RNA to Rigor
2026-09-18
DNA carryover is not a minor cleanup issue in RNA research; it can distort reverse-transcription assays, obscure transcript integrity, and weaken translational decisions. This thought-leadership article explains how DNase I (RNase-free) can be deployed as a strategically controlled preanalytical step across RNA extraction, in vitro transcription, chromatin studies, and long self-amplifying RNA quality assessment.
-
A-1331852: BCL-XL Inhibitor Workflow
2026-09-18
A-1331852 is a potent, selective BCL-XL inhibitor for linking target engagement with mitochondrial apoptosis in cancer research. This practical guide covers compound handling, apoptosis assay design, BCL-XL–BIM complex disruption, combination studies, and troubleshooting for reproducible preclinical workflows.
-
Berberine Hydrochloride: AMPK Assay Workflows
2026-09-17
Build reproducible Berberine hydrochloride workflows for AMPK signaling, LDL receptor regulation, lipid metabolism modulation, and cancer assays. This guide translates a cardiotoxicity study into practical assay design while separating evidence-backed findings from exploratory recommendations.
-
Short-Scale BIR Amplifies DNA Damage in Oocytes
2026-09-17
The reference study identifies short-scale break-induced replication (ssBIR) as a DNA synthesis response to double-strand breaks in fully grown mouse oocytes. Its combination of EdU labeling, damage-marker analysis, developmental-stage comparison, and replication-pathway inhibitors supports a model in which Rad51-dependent repair can amplify, rather than simply resolve, DNA damage.
-
Chloroquine Diphosphate in Ferroptosis Assays
2026-09-16
Build more informative cancer research workflows with Chloroquine Diphosphate as an autophagy, TLR7/TLR9, and cell-cycle perturbation tool. This guide shows how to pair it with orthogonal ferroptosis readouts, chemotherapy sensitization studies, and disciplined troubleshooting without mistaking autophagic flux changes for proof of cell death.
-
TAI-1: A Mechanistic Map of Hec1 Inhibition
2026-09-15
TAI-1 is a first-in-class Hec1 inhibitor that converts mitotic checkpoint disruption into a tractable cancer research strategy. This article distinguishes Hec1-driven mitotic stress from WEE1-associated transcription–replication damage and develops an assay framework for interpreting selectivity, synergy, and biomarker response.